Michael A. Morse, MD, MHS
Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3233
Durham, NC 27710
Appointment Telephone
919-668-6688
Office Telephone
919-681-3480
Fax Telephone
919-613-5228
- MD, Yale University School of Medicine (Connecticut), 1990
- Internal Medicine, University of Washington Medical Center, 1990-1993
- Hematology-Oncology, Duke University Medical Center, 1993-1996
- MHS, Duke University Medical Center, 2000
Clinical Interests
Gastrointestinal malignancies, hepatic tumors, immunotherapy, melanoma
Research Interests
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.
Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.
Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Advanced Liquid Logic, Inc.
- American Physician Institute for Advanced Profession
- American Society for Clinical Investigation
- Amgen, Inc.
- Archimedes
- Bayer
- Bristol-Myers Squibb
- Defined Health
- Etubics Corporation
- Genentech, Inc (Roche Holding)
- Georgia Society of Clinical Oncology
- Gerson Lehrman Group, Inc.
- Health Advances
- MarketLab dba Focus Pointe Global
- National Institutes of Health
- Novartis
- Onyx
- PPD, Inc.
- Pfizer Inc.
- PhytoChem Pharmaceuticals, Inc.
- Prometheus Laboratories Inc.
- Roche
- Sanofi-Aventis
- Schlesinger Associates
- Watermark
- West virginia University
- roda marketing
Representative Publications
Morse, MA; Secord, AA; Blackwell, K; Hobeika, AC; Sinnathamby, G; Osada, T; Hafner, J; Philip, M; Clay, TM; Lyerly, HK; Philip, R. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clinical Cancer Research. 2011;17:3408-3419.
(2011)
Abstract
Morse, MA; Hobeika, AC; Osada, T; Berglund, P; Hubby, B; Negri, S; Niedzwiecki, D; Devi, GR; Burnett, BK; Clay, TM; Smith, J; Lyerly, HK. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. Journal of Clinical Investigation. 2010;120:3234-3241.
(2010)
Abstract
Morse, MA; Wei, J; Hartman, Z; Xia, W; Ren, XR; Lei, G; Barry, WT; Osada, T; Hobeika, AC; Peplinski, S; Jiang, H; Devi, GR; Chen, W; Spector, N; Amalfitano, A; Lyerly, HK; Clay, TM. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 2010;126:2893-2903.
(2010)
Abstract
Osada, T; Hsu, D; Hammond, S; Hobeika, A; Devi, G; Clay, TM; Lyerly, HK; Morse, MA. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer. 2010;102:124-133.
(2010)
Abstract
Ribas, A; Kirkwood, JM; Atkins, MB; Whiteside, TL; Gooding, W; Kovar, A; Gillies, SD; Kashala, O; Morse, MA. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. Journal of Translational Medicine. 2009;7:68.
(2009)
Abstract
Morse, MA; Hobeika, AC; Osada, T; Serra, D; Niedzwiecki, D; Lyerly, HK; Clay, TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112:610-618.
(2008)
Abstract
Osada, T; Chong, G; Tansik, R; Hong, T; Spector, N; Kumar, R; Hurwitz, HI; Dev, I; Nixon, AB; Lyerly, HK; Clay, T; Morse, MA. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunology Immunotherapy. 2008;57:1115-1124.
(2008)
Abstract
Morse, MA; Hobeika, A; Osada, T; Niedzwiecki, D; Marcom, PK; Blackwell, KL; Anders, C; Devi, GR; Lyerly, HK; Clay, TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. Journal of Translational Medicine. 2007;5:42.
(2007)
Abstract
Osada, T; Clay, T; Hobeika, A; Lyerly, HK; Morse, MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunology Immunotherapy. 2006;55:1122-1131.
(2006)
Abstract
Hobeika, AC; Morse, MA; Osada, T; Ghanayem, M; Niedzwiecki, D; Barrier, R; Lyerly, HK; Clay, TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. Journal of Immunotherapy. 2005;28:63-72.
(2005)
Abstract
Morse, MA; Clay, TM; Hobeika, AC; Osada, T; Khan, S; Chui, S; Niedzwiecki, D; Panicali, D; Schlom, J; Lyerly, HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clinical Cancer Research. 2005;11:3017-3024.
(2005)
Abstract
Morse, MA; Garst, J; Osada, T; Khan, S; Hobeika, A; Clay, TM; Valente, N; Shreeniwas, R; Sutton, MA; Delcayre, A; Hsu, DH; Le Pecq, JB; Lyerly, HK. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. Journal of Translational Medicine. 2005;3:9.
(2005)
Abstract
Bunce, CJ; Morse, MA. A need for effective adjuvants. Current Opinion in Molecular Therapeutics. 2003;5:8-9.
(2003)
Abstract
Morse, MA; Clay, TM; Colling, K; Hobeika, A; Grabstein, K; Cheever, MA; Lyerly, HK. HER2 dendritic cell vaccines. Clinical Breast Cancer. 2003;3 Suppl 4:S164-S172.
(2003)
Abstract
Mosca, PJ; Hobeika, AC; Colling, K; Clay, TM; Thomas, EK; Caron, D; Lyerly, HK; Morse, MA. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. Journal of Leukocyte Biology. 2002;72:546-553.
(2002)
Abstract
Clay, TM; Hobeika, AC; Mosca, PJ; Lyerly, HK; Morse, MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clinical Cancer Research. 2001;7:1127-1135.
(2001)
Abstract
